Form 4: Teva EVP Christine Fox sells 30,000 shares
Statement of Changes in Beneficial Ownership (Form 4)
Teva’s U.S. Commercial chief sold 30,000 shares at $25.1107 and now holds 28,384 shares.
Summary
- On 2025-11-14, EVP/Head of U.S. Commercial Christine Fox sold 30,000 Teva ordinary shares at $25.1107 per share (transaction code S).
- Remaining beneficial ownership after the sale: 28,384 shares, held directly.
- Estimated gross proceeds from the sale: $753,321 based on the reported price and volume.
- The Form 4 was signed by attorney-in-fact Dov Bergwerk on 2025-11-18.
- Ordinary shares may be represented by ADSs; each ADS currently represents one ordinary share.
Sentiment
Score: 4
Explanation: Insider sale by a senior executive is a modest negative signal, partially offset by continued share ownership; no operational or financial data provided.
Positives
- Executive retains 28,384 shares post-transaction, indicating continued equity exposure.
- Transparent disclosure of direct ownership; no derivative transactions reported in this filing.
Negatives
- Insider sale by a senior executive (30,000 shares) may be viewed negatively by some investors.
- Sale size (~$753,321) represents a meaningful reduction in the executive’s directly held shares.
Future Outlook
No forward-looking statements or guidance provided in this Form 4.
Industry Context
Insider transactions are common across pharmaceuticals and broader markets; single executive sales typically have limited read-through to fundamentals absent accompanying operational updates.
Comparison to Industry Standards
- Not applicable: This Form 4 reports insider share activity rather than operating or financial performance; comparisons to peers (e.g., Pfizer, Novartis, Viatris) are not meaningful in this context.
Stakeholder Impact
- Shareholders: Potential short-term negative sentiment from a senior executive’s share sale.
- Employees: No direct impact disclosed.
- Customers/Suppliers: No direct impact disclosed.
- Creditors: No direct impact disclosed.
Key Dates
| Date | Description |
|---|---|
| 2025-11-14 | Transaction date for sale of 30,000 ordinary shares (code S) |
| 2025-11-18 | Form signed by attorney-in-fact for Christine Fox |
Keywords
Teva Pharmaceutical Industries, TEVA, insider transaction, Form 4, Christine Fox, executive stock sale, ordinary shares, American Depositary Shares, beneficial ownership, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.